Tag: ASGCT
Nexcella Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Resp…...
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201100% (8/8) overall response rate and 63% (5/8) complete response (MRD...
Skyline Therapeutics to Present at the ASGCT 26th Annual Meeting ...
SHANGHAI, May 3, 2023 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company dedicated to developing unique and novel solutions to address unmet...
Athenex、美國德薩斯州兒童癌症中心及 Baylor College of Medicine 的 Center for Cell and Gene...
數據由德薩斯州兒童癌症中心的研究人員提供11 名患者中顯示一名出現部分反應、一名出現完全反應，及四名為穩定疾病GD2 CAR NKT 細胞耐受，並無可限制劑量的毒性經疾病負擔（AUC/居里評分）標準化的 CAR-NKT AUC 與治療反應相關。 紐約水牛城, May 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX) 作為一家致力於發現、開發和商業化癌症和相關疾病療法與治療的全球生物製藥公司，在其...
Generation Bio Presents Preclinical Data Demonstrating Broad Potential of Gene Therapy...
Durable, therapeutically relevant levels of anti-SARS-CoV-2 spike antibodies produced from the liver in a mouse model Next-generation rapid enzymatic synthesis of...
Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting
Two Oral Presentations to Cover iPSC-derived Cell-based Cancer Immunotherapy Pipeline Company to Host Investor Event on May 13 to Highlight Interim...